

Adam C Elnaggar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8813052/publications.pdf>

Version: 2024-02-01

29
papers

597
citations

840776

11
h-index

642732

23
g-index

29
all docs

29
docs citations

29
times ranked

1081
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 246.	2.5	4
2	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. <i>Gynecologic Oncology</i> , 2020, 159, 150-156.	1.4	43
3	Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. <i>Journal of Personalized Medicine</i> , 2020, 10, 252.	2.5	20
4	NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 896-909.	4.9	200
5	Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. <i>Gynecologic Oncology</i> , 2018, 151, 501-505.	1.4	13
6	Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial. <i>Gynecologic Oncology</i> , 2018, 151, 124-128.	1.4	11
7	Abstract 1923: Identification and validation of Integrin-Linked Kinase (ILK) signaling as a therapeutic target for ovarian cancer. , 2018, , .		0
8	Abstract 3071: The role of Apela in high-grade serous ovarian cancer. , 2018, , .		0
9	Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. <i>Oncogene</i> , 2017, 36, 168-181.	5.9	99
10	Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. <i>Gynecologic Oncology</i> , 2017, 144, 451-455.	1.4	2
11	A comparison of outcomes following robotic-assisted staging and laparotomy in patients with early stage endometrioid adenocarcinoma of the uterus with uterine weight under 480Ág. <i>Gynecology and Minimally Invasive Therapy</i> , 2016, 5, 25-29.	0.9	5
12	Incidence and contributing factors to termination of the patient-physician relationship. <i>Gynecologic Oncology Reports</i> , 2016, 17, 42-44.	0.6	3
13	Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 1107-1115.	3.4	15
14	Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1717-1721.	2.5	26
15	Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series. <i>PLoS ONE</i> , 2016, 11, e0156985.	2.5	5
16	Abstract LB-036: Elevated STAT3 expression in ovarian tumor ascites regulates invasion and metastasis: a promising therapeutic target. , 2016, , .		0
17	Effect of Transdermal Scopolamine for the Prevention of Postoperative Nausea and Vomiting Associated With Robotic Gynecologic Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Journal of Gynecologic Surgery</i> , 2015, 31, 266-271.	0.1	3
18	Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. <i>Gynecologic Oncology</i> , 2015, 138, 689-693.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. <i>Gynecologic Oncology</i> , 2015, 139, 413-418.	1.4	18
20	Abstract POSTER-THER-1413: Targeting constitutively-activated STAT3 in hypoxic ovarian cancer. , 2015, , .		0
21	HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 2316-2327.	0.9	71
22	Guided outcomes in learned efficiency model in clinical medical education: a randomized controlled trial of self-regulated learning. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 544.e1-544.e7.	1.3	2
23	In Reply. <i>Obstetrics and Gynecology</i> , 2014, 123, 184.	2.4	0
24	Abstract LB-28: Suppression of ovarian tumor growth and metastasis with a STAT3 inhibitor, HO-3867, in preclinical orthotopic models and ex vivo cultures of ovarian cancer. , 2014, , .		0
25	Endometrial cancer in a 15-year-old girl: A complication of Cowden Syndrome. <i>Gynecologic Oncology Case Reports</i> , 2013, 3, 18-19.	0.9	11
26	Risk Factors for Anal Intraepithelial Neoplasia in Women With Genital Dysplasia. <i>Obstetrics and Gynecology</i> , 2013, 122, 218-223.	2.4	23
27	Neonatal functional lung maturity relative to gestational age at delivery, fetal growth, and pregnancy characteristics in triplet births. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 78-83.	1.5	7
28	Neuroendocrine Carcinoma of the Vagina in Pregnancy. <i>Obstetrics and Gynecology</i> , 2012, 119, 445-447.	2.4	2
29	Keratosis reduces sensitivity of anal cytology in detecting anal intraepithelial neoplasia. <i>Gynecologic Oncology</i> , 2012, 124, 292-295.	1.4	5